Panel Risk-Based Quality Management · Clin Ops in Europe's Emerging Biopharma
The EU AI Act: Death Knell or Chance to Prove Value?
Wed, Oct 30, 2024 · 9:40–10:17 AM CET InterContinental Barcelona
About this session
Session: UNDERSTANDING THE EU AI ACT: INSIGHTS FROM ALL STAKEHOLDERS IN CLINICAL TRIALS, FROM EMERGING TO LARGE PHARMA
The EU AI act is set to shake-up the entire European tech sector. Biotechs, in particular, are concerned about the key steps they must take in order to comply. Currently, there are two conflicting opinions regarding the Act—naturally on one end some are worried regulation will stifle innovation in Europe. On the other end, some are worried the Act does not go far enough. In this discussion, leaders from across the biotech industry will explore the steps required to comply with the act, the day-to-day operational changes these steps will induce, the potential long-term impacts, and how founders and executives can de-risk the entire process.
Speakers
-
Digital Product Line Owner, Clinical Study Design · Sanofi
Panelist
-
Strategic Partnering, Business Development & Licensing Director · Insilico Medicine
Panelist
-
Senior Associate · LongeVC
Panelist
